PRESS-RELEASE ·Filed May 7, 2026

CYTK

Cytokinetics, Incorporated
BEARISH
Impact 6/10
Horizondays Processed4mo ago WireGlobeNewswire
Press release: offering
Actionable Insight ▼ Bearish

Monitor for potential downward pressure on CYTK shares as the offering closes May 8, given the dilutive nature. The stock may trade around the $71 offering price near-term. Watch for any post-offering price support from underwriters.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
CYTK ▲ +2.91% at T+60d
SHORT call ✗ call lost -2.91% · α vs SPY +0.93% · entry $74.29 → $76.45
Entry anchored
May 6, 2026
via day open
T+1d
+3.53%
call -3.53% · α -2.70%
$76.91
settled 5mo ago
T+5d
+3.94%
call -3.94% · α -2.44%
$77.22
settled 5mo ago
T+20d
-4.82%
call +4.82% · α +7.95%
$70.71
settled 4mo ago
T+60d
+2.91%
call -2.91% · α +0.93%
$76.45
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Cytokinetics priced a $700 million public offering of 9.86 million shares at $71.00 per share, with an underwriter option for an additional 1.48 million shares. The offering represents approximately 7.3% dilution to existing shareholders and will close on May 8, 2026.

Key Financial Metrics

Deal Value
$700.0M

Key Facts

  • 9,859,155 shares offered at $71.00/share for ~$700M gross proceeds
  • Underwriters have 30-day option to purchase up to 1,478,873 additional shares
  • Offering represents ~7.3% dilution (8.4% if greenshoe exercised)
  • Morgan Stanley, Goldman Sachs, J.P. Morgan, and Jefferies are joint book-runners
  • Closing expected May 8, 2026

Financial Impact

~$700M gross proceeds, ~7-8% dilution to existing shareholders

dilutionshare count

Risk Factors

  • Equity dilution of ~7-8%
  • Potential overhang from additional shares if greenshoe exercised
  • Use of proceeds not specified, adding uncertainty

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (27 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3289552
32 reports for CYTK
Performance horizon
88% Hit rate 7 of 8 directional calls best @ T+20▲ +10.38%Mar 31, 2026
Filters
Rows
Reports for CYTK — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
BEARISH ★ 5/10
$69.31 $67.59▲ +2.48%▲ +4.59%$65.60 (+5.35%)
Sep 11, 2026
20d ago
Insider Cluster
NEUTRAL ★ 2/10
$72.45 $67.56▼ −6.75%▼ −6.86%$65.60 (−9.45%)
Sep 1, 2026
4w ago
Insider Cluster
NEUTRAL ★ 2/10
$71.40 $74.11▲ +3.80%▲ +3.71%$65.60 (−8.12%)
Aug 31, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$71.40 $74.11▲ +3.80%▲ +3.71%$65.60 (−8.12%)
Aug 29, 2026
4w ago
Press Release
BULLISH ★ 7/10
$70.91 $75.35▲ +6.26%▲ +6.40%$65.60 (−7.49%)
Aug 28, 2026
5w ago
8-K
BULLISH ★ 7/10
$72.09 $72.72▲ +0.87%▲ +0.76%$65.60 (−9.00%)
Jul 30, 2026
9w ago
Insider Cluster
NEUTRAL ★ 2/10
$80.42 $81.37▲ +1.18%▼ −2.44%$65.60 (−18.43%)
Jul 27, 2026
9w ago
Insider Cluster
NEUTRAL ★ 2/10
$80.62 $77.13▼ −4.33%▼ −5.40%$65.60 (−18.63%)
Jul 23, 2026
10w ago
Press Release
NEUTRAL ★ 2/10
$80.74 $80.42▼ −0.40%▼ −0.77%$65.60 (−18.75%)
Jul 14, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$81.93 $79.11▼ −3.44%▼ −2.15%$65.60 (−19.93%)
Showing 10 of 32

US Market Status

Market Closed — Opens Mon (65h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 7, 2026